日报更新时间：07-02 06:53
周报更新时间：01-09 11:34
今开价：165.35
最高价：171.01
成交量：5.03007E7
昨收价：165.07
最低价：165.35
最新价：165.85
中文名称：阿里拉姆制药
英文名称：Alnylam Pharmaceuticals
行业：医疗
简介：Alnylam Pharmaceuticals, Inc.是一家特拉华州公司，成立于2003年5月
电话：1-617-5518200
Alnylam Pharmaceuticals于2002由Phillip Sharp、Paul Schimmel、Dave Bartel、Thomas Tuschl 和 Phillip Zamore创立，是一家生物制药公司，公司临床开发计划包含： Patisiran和Revusiran，用于治疗转甲蛋白媒介的类淀粉变性症，目前处于III期临床试验阶段； ALN-AT3，用于血友病及罕见的出血性疾病，目前处于I期临床试验阶段； ALN-CC5，用于治疗补体媒介的疾病，目前处于I/II期临床试验阶段； ALN-PCSsc，用于高胆固醇血症，目前处于I期临床试验阶段； ALN-AS1，用于治疗肝性吡咯紫质沉着症； ALN-AC3，用于治疗高三酸甘油脂血症； ALN-GO1，用于治疗第一型原发性高草酸盐尿症； ALN-AAT，用于治疗α-1胰蛋白酶缺乏性肝病； ALN-TMP，用于治疗乙型地中海贫血及铁质过度负担疾病； ANGPTL3，用于治疗高三酸甘油脂血症及混合型高脂血症； ALN-AGT，用于治疗妊娠的高血压疾病，包含先兆子痫(妊娠毒血症)； ALN-HBV，用于治疗B型肝炎病毒； ALN-HDV，用于治疗HDV感染； ALN-PDL，用于治疗慢性肝脏感染。阿里拉姆制药公司的策略联盟及合作协议伙伴包含：诺华、百健艾迪、美敦力、麦迪逊医药、孟山都、Ionis Pharmaceuticals, Inc.、英属哥伦比亚大学、Genzyme Corporation（健赞，原NASDAQ:GENZ）、F. Hoffmann-La Roche Ltd（全球排名第三的基因测序公司(NGS)，仅次于Illumina和Thermo Fisher Scientific）、Tekmira Pharmaceuticals Corporation（原NASDAQ:TKMR）、Acuitas Therapeutics Inc.、Takeda Pharmaceutical Company Limited（日本武田藥品）、Protiva Biotherapeutics, Inc.、Ascletis BioScience Co., Ltd、立派制药公司（Cubist Pharmaceuticals, Inc.，原NASDAQ:CBST，于2014年12月8日被默克公司以84亿美金收购）及协和发酵麒麟（Kyowa Hakko Kirin Co.）。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2019-05-14 | Maraganore (John M) | Chief Executive Officer | Buy | 49457 | 16.43 |
| 2019-05-14 | Maraganore (John M) | Chief Executive Officer | Sell | 49457 | 70.00 |
| 2019-04-14 | Sharp (Philip A. Ph.D.) | Director | Sell | 2200 | 89.03 |
| 2019-04-14 | Sharp (Philip A. Ph.D.) | Director | Sell | 400 | 89.97 |
| 2019-04-14 | Sharp (Philip A. Ph.D.) | Director | Sell | 600 | 91.40 |
| 2019-04-14 | Sharp (Philip A. Ph.D.) | Director | Sell | 11800 | 87.86 |
| 2019-04-14 | Sharp (Philip A. Ph.D.) | Director | Buy | 15000 | 22.09 |
| 2019-04-08 | Maraganore (John M) | Chief Executive Officer | Buy | 61 | -- |
| 2019-04-08 | Keating (Laurie Bartlett) | Officer | Buy | 41 | -- |
| 2019-04-08 | Greenstreet (Yvonne L M.D.) | Chief Operating Officer | Buy | 49 | -- |
| 2019-04-08 | Vaishnaw (Akshay K) | Officer | Buy | 51 | -- |
| 2019-04-08 | Greene (Barry E) | President | Buy | 52 | -- |
| 2018-11-20 | Maraganore (John M) | Chief Executive Officer | Buy | 98636 | 21.35 |
| 2018-11-20 | Maraganore (John M) | Chief Executive Officer | Sell | 59940 | 72.68 |
| 2018-10-17 | Maraganore (John M) | Chief Executive Officer | Buy | 17 | -- |
| 2018-10-17 | Vaishnaw (Akshay K) | Officer | Buy | 21 | -- |
| 2018-10-17 | Keating (Laurie Bartlett) | Officer | Buy | 14 | -- |
| 2018-10-17 | Greene (Barry E) | President | Buy | 21 | -- |
| 2018-08-29 | Greenstreet (Yvonne L M.D.) | Chief Operating Officer | Sell | 2500 | 120.00 |
| 2018-08-12 | Vaishnaw (Akshay K) | Officer | Sell | 766 | 90.95 |
| 2018-08-12 | Greenstreet (Yvonne L M.D.) | Chief Operating Officer | Sell | 3084 | 90.95 |
| 2018-08-12 | Greenstreet (Yvonne L M.D.) | Chief Operating Officer | Buy | 7500 | -- |
| 2018-08-12 | Mason (Michael P) | Officer and Treasurer | Sell | 449 | 90.95 |
| 2018-08-12 | Mason (Michael P) | Officer and Treasurer | Buy | 1012 | -- |
| 2018-08-12 | Vaishnaw (Akshay K) | Officer | Buy | 1724 | -- |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| First Trust Advisors L.P. | 1192495 | 1.12% | 14439 | 1.23% | 2019-03-31 |
| Dodge & Cox | 4998001 | 4.69% | 307750 | 6.56% | 2019-03-31 |
| Baillie Gifford & Co Limited. | 5684504 | 5.34% | 937654 | 19.75% | 2019-03-31 |
| BlackRock Inc | 6428127 | 6.03% | 282322 | 4.59% | 2019-03-31 |
| Vanguard Group Inc | 8659091 | 8.13% | 439757 | 5.35% | 2019-03-31 |
| Fidelity Management & Research Company | 9909880 | 8.91% | -371093 | -3.61% | 2019-07-31 |
| Wellington Management Company LLP | 14832598 | 13.92% | 766371 | 5.45% | 2019-03-31 |
| Fidelity Management and Research Company | 15787566 | 14.82% | 760813 | 5.06% | 2019-03-31 |
| FMR Inc | 15945666 | 14.97% | 791113 | 5.22% | 2019-03-31 |
| Fidelity Management Trust Co | 3952347 | 3.55% | -45779 | -1.15% | 2019-07-31 |
| T. Rowe Price Associates, Inc. | 3483589 | 3.27% | -192236 | -5.23% | 2019-03-31 |
| Maverick Capital Ltd | 3210387 | 3.01% | 406436 | 14.50% | 2019-03-31 |
| Morgan Stanley - Brokerage Accounts | 1220361 | 1.15% | 37462 | 3.17% | 2019-03-31 |
| BB Biotech AG | 1631089 | 1.53% | 59700 | 3.80% | 2019-03-31 |
| Bellevue Asset Management AG | 1723341 | 1.55% | 69052 | 4.17% | 2019-07-31 |
| Hartford Funds Management Company, LLC | 2004352 | 1.80% | -- | -- | 2019-07-31 |
| BlackRock Fund Advisors | 2528376 | 2.27% | 14625 | 0.58% | 2019-07-31 |
| State Street Corporation | 2748494 | 2.58% | 343759 | 14.30% | 2019-03-31 |
| Fidelity SelectCo, LLC | 2913234 | 2.62% | 400 | 0.01% | 2019-07-31 |
| Vanguard Investments Australia Ltd | 2980418 | 2.68% | 5418 | 0.18% | 2019-07-31 |
| Geode Capital Management, LLC | 1831066 | 1.72% | 950303 | 107.90% | 2018-12-31 |
| UBS Asset Mgmt Americas Inc | 1417490 | 1.33% | 96532 | 7.31% | 2018-12-31 |
| Goldman Sachs Group Inc | 1119388 | 1.05% | 178810 | 19.01% | 2018-12-31 |
| Perceptive Advisors LLC | 1197994 | 1.13% | -648917 | -35.14% | 2018-09-30 |
| Orbimed Advisors, LLC | 1265966 | 1.25% | -- | -- | 2018-06-30 |
| BlackRock Institutional Trust Company NA | 2345836 | 2.32% | -53856 | -2.24% | 2018-06-30 |
| Point72 Asset Management, L.P. | 1356408 | 1.34% | 448362 | 49.38% | 2018-06-30 |
| Sanofi | 10554134 | 10.59% | 9268869 | 721.16% | 2017-12-31 |
| State Street Corp | 2250242 | 2.24% | 118425 | 5.56% | 2018-06-30 |
| Morgan Stanley Investment Management Inc | 1166030 | 1.16% | 6176 | 0.53% | 2018-06-30 |
| Gilder Gagnon Howe & CO LLC | 1094716 | 1.09% | -115706 | -9.56% | 2018-06-30 |
| Goldman, Sachs & Co. | 751215 | 0.75% | -178479 | -19.20% | 2018-06-30 |
| Pictet Asset Management SA | 646038 | 0.64% | 292564 | 82.77% | 2018-03-31 |
| 12 West Capital Management LP | 700000 | 0.70% | -- | -- | 2018-03-31 |
| Blue Ridge CapHldgsLLC/BluRdgCapOSHldgs | 1338300 | 1.34% | -193599 | -12.64% | 2017-12-31 |
| NORGES BANK | 742261 | 0.74% | 77598 | 11.67% | 2017-12-31 |
| BlackRock Advisors LLC | 866689 | 0.87% | -- | -- | 2018-02-28 |
| HHG PLC | 683020 | 0.74% | 15687 | 2.35% | 2017-09-30 |
| Vanguard Specialized Funds | 6670468 | 6.69% | -1878889 | -21.98% | 2017-12-31 |
| D. E. Shaw & Co LP | 982454 | 1.06% | 248804 | 33.91% | 2017-09-30 |
| RTW INVESTMENTS, LLC | 623338 | 0.67% | -417269 | -40.10% | 2017-09-30 |
| Eastern Capital LTD | 3802341 | 4.47% | -1126775 | -22.86% | 2016-02-25 |
| Slate Path Capital LP | 1225000 | 1.43% | 90000 | 7.93% | 2016-09-30 |
| Bridger Management LLC | 983040 | 1.15% | 296031 | 43.09% | 2016-09-30 |
| Jennison Associates LLC | 781656 | 0.91% | -193769 | -19.87% | 2016-09-30 |
| Franklin Advisers Inc | 714000 | 0.83% | 122000 | 20.61% | 2016-09-30 |
| Vanguard Specialized Funds-Vanguard Health Care Fund | 5030100 | 1.00% | 471974283 | 0.10% | 1999-11-30 |
| Wellington Management Group LLP | 8947136 | 1.00% | 839509771 | 0.10% | 1999-11-30 |
| FMR LLC | 11539663 | 1.00% | 1082766579 | 0.10% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| T. Rowe Price Health Sciences Fund | 598973 | 0.54% | -3900 | -0.65% | 2019-06-30 |
| Vanguard Health Care Fund | 9842666 | 8.85% | 747116 | 8.21% | 2019-03-31 |
| Fidelity Growth Company Commingled Pool | 3890938 | 3.50% | 3600 | 0.09% | 2019-06-30 |
| Dodge & Cox Stock Fund | 3197761 | 2.88% | 190000 | 6.32% | 2019-06-30 |
| Vanguard Total Stock Market Index Fund | 2940978 | 2.64% | 492 | 0.02% | 2019-06-30 |
| Vanguard Mid-Cap Index Fund | 2595222 | 2.33% | 38316 | 1.50% | 2019-06-30 |
| Vanguard Extended Market Index Fund | 1302477 | 1.17% | -8874 | -0.68% | 2019-06-30 |
| First Trust NYSE Arca Biotech Fund | 1270956 | 1.14% | -3063 | -0.24% | 2019-07-31 |
| Hartford MidCap Fund | 1238046 | 1.11% | -- | -- | 2019-06-30 |
| T. Rowe Price Mid-Cap Growth Fund | 1150000 | 1.03% | -- | -- | 2019-06-30 |
| iShares Nasdaq Biotechnology ETF | 1051685 | 0.95% | 10952 | 1.05% | 2019-07-30 |
| UBS: Global Equity-UBS | 856794 | 0.77% | -- | -- | 2019-03-31 |
| Fidelity | 808979 | 0.73% | -2382 | -0.29% | 2019-06-30 |
| SPDR | 803172 | 0.72% | 12480 | 1.58% | 2019-07-31 |
| Vanguard Growth Index Fund | 761288 | 0.68% | 25678 | 3.49% | 2019-06-30 |
| Vanguard Mid-Cap Growth Index Fund | 678187 | 0.61% | 27278 | 4.19% | 2019-06-30 |
| Fidelity Advisor | 545086 | 0.51% | -- | -- | 2019-04-30 |
| Federated Kaufmann Large Cap Fd | 509400 | 0.48% | -121900 | -19.31% | 2018-12-31 |
| American Century Ultra | 558000 | 0.55% | 172000 | 44.56% | 2018-09-30 |
| T. Rowe Price Institutional Lrg Cp Gr Fd | 840717 | 0.83% | -90764 | -9.74% | 2018-03-31 |
| T. Rowe Price Growth Stock Fund | 1815300 | 1.80% | 77180 | 4.44% | 2018-03-31 |
| Vanguard Mid Cap Index I | 2147154 | 2.13% | 16889 | 0.79% | 2018-07-31 |
| T. Rowe Price New Horizons | 434088 | 0.43% | -867300 | -66.64% | 2018-06-30 |
| Vanguard Mid-Cap Growth ETF | 548774 | 0.55% | 2468 | 0.45% | 2018-07-31 |
| Federated Kaufmann Large Cap A | 585000 | 0.58% | 202210 | 52.83% | 2018-06-30 |
| Vanguard Growth Index Inv | 636255 | 0.63% | -3651 | -0.57% | 2018-07-31 |
| First Trust NYSE Arca Biotech ETF | 701562 | 0.54% | -- | -- | 2018-09-13 |
| Hartford MidCap A | 837832 | 0.83% | 275813 | 49.08% | 2018-07-31 |
| Vanguard Health Care Inv | 7782825 | 7.74% | 893408 | 12.97% | 2018-06-30 |
| Dodge & Cox Stock | 2813861 | 2.80% | -- | -- | 2018-06-30 |
| Vanguard Total Stock Mkt Idx | 2272798 | 2.26% | 9114 | 0.40% | 2018-07-31 |
| T. Rowe Price Mid-Cap Growth | 1700000 | 1.69% | -50000 | -2.86% | 2018-06-30 |
| iShares Nasdaq Biotechnology | 1140239 | 0.87% | -2172 | -0.19% | 2018-09-12 |
| Vanguard Extended Market Idx Inv | 1106380 | 1.10% | 1305 | 0.12% | 2018-07-31 |
| T. Rowe Price Health Sciences | 861255 | 0.86% | -872477 | -50.32% | 2018-06-30 |
| Morgan Stanley Inst Growth I | 378114 | 0.38% | 107136 | 39.54% | 2018-03-31 |
| T. Rowe Price Instl Large Cap Growth | 840717 | 0.84% | -90764 | -9.74% | 2018-03-31 |
| T. Rowe Price Growth Stock | 1815300 | 1.81% | 77180 | 4.44% | 2018-03-31 |
| Dodge & Cox Balanced | 445800 | 0.44% | -305200 | -40.64% | 2018-03-31 |
| BlackRock Health Sciences Opps Inv A | 877400 | 0.87% | 24700 | 2.90% | 2018-03-31 |
| Dodge & Cox Global Stock | 671900 | 0.67% | -160900 | -19.32% | 2017-12-31 |
| Vanguard Small Cap Index | 1050826 | 1.05% | 2714 | 0.26% | 2018-02-28 |
| Vanguard Small Cap Growth Index Inv | 593240 | 0.60% | -556903 | -48.42% | 2017-12-31 |
| T. Rowe Price Instl Mid-Cap Equity Gr | 291000 | 0.34% | 9500 | 3.37% | 2016-09-30 |
| Vanguard Explorer Inv | 380080 | 0.44% | 10742 | 2.91% | 2016-09-30 |
| Fidelity® Select Biotechnology Portfolio | 1800278 | 2.10% | 28900 | 1.60% | 2015-09-30 |
| Fidelity® Series Growth Company Fund | 1341551 | 1.60% | 20900 | 1.60% | 2015-09-30 |
| Prudential Jennison Health Sciences | 787111 | 0.90% | -- | -- | 2015-09-30 |
| Fidelity® Blue Chip Growth Fund | 685563 | 0.80% | -- | -- | 2015-09-30 |
| VA CollegeAmerica Small Cap World | 647603 | 0.80% | -104000 | -13.80% | 2015-09-30 |
| Prudential Jennison Mid Cap Growth | 496075 | 0.60% | -- | -- | 2015-09-30 |
| Fidelity® Growth Company Fund | 4899854 | 5.80% | 22199 | 0.50% | 2015-09-30 |
| 巴里E.格林 | 巴里E.格林先生为本公司总裁兼首席营运官。自2007年12月以来，他曾担任总裁兼首席营运官，他在2003年10月加入本公司并担任首席运营官，并从2004年2月至2005年12月担任司库。 |
|---|---|
| 约翰M. 马拉甘尔 | 约翰M. 马拉甘尔博士担任本公司首席执行官，董事。从2002年12月至2007年12月马拉甘尔博士还担任本公司总裁。从2000年4月至2002年12月，马拉甘尔博士担任千年制药公司产品开发战略高级副总裁。 |
| 阿克沙伊K. 威士纳 | 阿克沙伊K. 威士纳博士担任本公司执行副总裁，首席医疗官。威士纳博士2006年1月以来入职本公司，最近担任的职务是自2011年6月以来担任本公司高级副总裁以及首席医疗官。 |
| 迈克尔P.梅森 | 迈克尔P.梅森先生担任本公司财务副总裁，司库。从2005年12月到2011年2月，梅森先生担任公司总监，并从2009年8月至2011年2月，担任高级财务总监。从2006年6月至2009年7月，梅森先生担任财务总监。 |
| 约翰·K·克拉克 | 约翰·K·克拉克先生是阿尔尼拉姆制药公司的董事会独立主席。自从1997年红色合作伙伴公司，一家专注于医疗保健的风险投资公司创办以来，克拉克先生一直担任其管理合伙人。克拉克先生还担任动量制药公司和Verastem公司的董事，并曾任Sirtris制药公司和Visicu公司的董事。 |
|---|---|
| 约翰M. 马拉甘尔 | 约翰M. 马拉甘尔博士担任本公司首席执行官，董事。从2002年12月至2007年12月马拉甘尔博士还担任本公司总裁。从2000年4月至2002年12月，马拉甘尔博士担任千年制药公司产品开发战略高级副总裁。 |
| 菲利普A.夏普 | 菲利普A.夏普博士是本公司董事。夏普博士是美国麻省理工学院（MIT）大卫·科赫综合癌症研究学会学院教授，是麻省理工学院麦戈文脑研究院的创始主任。 |
| 史蒂芬·保罗 | 史蒂芬·保罗博士担任本公司的独立董事，保罗博士是阿佩尔阿尔茨海默氏病研究所主任，是康乃尔大学威尔康乃尔医学院的神经病学（神经科学），精神病学和药理学教授。 |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 1
阿里拉姆制药盘前涨4.1%，此前黑石集团向其投资20亿美元。